CVN293, an Investigational Inhibitor of KCNK13 Targeting NLRP3‐Mediated Neuroinflammation in Neurodegenerative Disease: A Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics.
This Phase 1 study demonstrated a favourable tolerability profile for CVN293 in healthy adults and supports the continued development of this novel KCNK13 inhibitor for neurodegenerative diseases driven by neuroinflammation.
Authors
- Louise Dickson (ORCID: https://orcid.org/0000-0003-0550-7495)
- Philip H. C. Kremer (ORCID: https://orcid.org/0000-0003-0483-841X)
- Roberto Tolando
- Craig B. Thompson (ORCID: https://orcid.org/0000-0003-3580-2751)
- Martin Bexon (ORCID: https://orcid.org/0000-0002-5361-4343)
- Kim L. Matthews
- Lee A. Dawson
- Dino Ossola
- Jasminne Castricum
- Celina Scholl
- Sagar Vaidaya
- Graham Scott
- Michelle Charles
- Mark Carlton
- Nicola Brice
Institutions
- East Sussex County Council (GB)
- Cambridge Environmental Research Consultants (United Kingdom) (GB)
- Centre for Human Drug Research (NL)
- Queen Victoria Hospital NHS Foundation Trust (GB)
- Bexon Clinical Consulting (United States) (US)
- European Organization for Nuclear Research (CH)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_106386
- Primary Topic
- Inflammasome and immune disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00